

			Clinical Trials			EMA/MHRA Approval	To Patients
			Phase I (safety)	Phase 2 (efficacy)	Phase 3 (proof)		
SMN-dependent	antisense oligonucleotide (targeting <i>SMN2</i>)						
	Ionis/Biogen Spinraza/nusinersen						
	Ionis/Biogen Spinraza/nusinersen (High Dose)						
	Ionis/Biogen BIIB115/salanersen						
	<i>SMN1</i> gene replacement						
	Novartis Gene Therapies/Novartis Zolgensma/onasemnogene abeparvovec (intravenous)					SMA Type 1 Only *	
	Novartis Gene Therapies/Novartis Zolgensma/onasemnogene abeparvovec (intrathecal)						
	small molecule (targeting <i>SMN2</i>)						
	PTC/Roche Evrysdi/risdiplam (oral solution)						
	PTC/Roche Evrysdi/risdiplam (tablet form)						
Combination	combined treatments						
	Scholar Rock SRK-015/apitegromab	nusinersen or risdiplam					
	Biohaven Pharmaceuticals taldefgrobep alfa	nusinersen or risdiplam or onasem. abeparv.					
	Roche GYM329/RO7204239	PTC/Roche risdiplam					
SMN-independent	muscle-directed						
	NMD Pharma NMD670		SMA Type 3 Only *				

* Subject to country eligibility criteria